文献速递肺栓塞与肺血管病

NEDD9是肺循环中血小板-内皮黏附的新型可调控介质

NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

本研究旨在识别缺氧敏感、可调控的血小板-肺动脉内皮细胞黏附介质。网络医学分析发现NEDD9在缺氧血栓体网络中富集,缺氧(0.2% O2)24小时通过HIF-1α依赖性方式上调NEDD9。定制抗NEDD9抗体靶向NEDD9-P选择素相互作用,抑制活化血小板与对照及CTEPH患者肺动脉内皮细胞的黏附,并在三种动物模型中减少血小板-肺内皮聚集、ADP诱导的肺动脉高压及慢性肺血栓栓塞性重塑。

要点

  • NEDD9在缺氧下经HIF-1α依赖性上调,定位至肺动脉内皮细胞膜表面。
  • 抗NEDD9抗体靶向NEDD9-P选择素相互作用,抑制血小板-内皮黏附。
  • NEDD9-/-小鼠或抗NEDD9抗体治疗减少ADP诱导的肺动脉高压和血栓栓塞性重塑。

核心结论

  • NEDD9-P选择素蛋白-蛋白相互作用是可调控靶点,可抑制血小板-肺内皮黏附及血栓栓塞性血管重塑。
  • 该靶点对缺氧信号通路增强相关疾病(包括CTEPH)具有潜在治疗意义。

研究设计与样本

  • 研究采用网络医学分析缺氧处理的人肺动脉内皮细胞蛋白-蛋白相互作用。
  • 结合液相色谱-质谱和微量热泳动数据开发新型抗体,在CTEPH患者细胞和三种动物模型中体内外验证。

主要发现

  • 缺氧(0.2% O2)24小时较常氧增加HIF-1α依赖性NEDD9上调。
  • NEDD9定位于对照供者和CTEPH患者细胞的质膜表面,在动脉内膜切除标本中与P选择素共定位。
  • 定制抗NEDD9抗体靶向NEDD9-P选择素相互作用,抑制活化血小板与对照供者及CTEPH患者肺动脉内皮细胞的黏附。
  • 与对照小鼠相比,NEDD9-/-小鼠或抗NEDD9抗体治疗的野生型小鼠中ADP诱导的血小板-肺内皮聚集和肺动脉高压减少。
  • 抗NEDD9抗体减少体内慢性肺血栓栓塞性重塑。

临床怎么用

  • NEDD9-P选择素相互作用可作为抑制血小板-肺内皮黏附和血栓栓塞性重塑的潜在治疗靶点。
  • 抗NEDD9抗体在CTEPH患者细胞和动物模型中显示抑制黏附和重塑的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Data on the molecular mechanisms that regulate platelet-pulmonary endothelial adhesion under conditions of hypoxia are lacking, but may have important therapeutic implications. Objectives: To identify a hypoxia-sensitive, modifiable mediator of platelet-pulmonary artery endothelial cell adhesion and thrombotic remodeling. Methods: Network medicine was used to profile protein-protein interactions in hypoxia-treated human pulmonary artery endothelial cells. Data from liquid chromatography-mass spectrometry and microscale thermophoresis informed the development of a novel antibody (Ab) to inhibit platelet-endothelial adhesion, which was tested in cells from patients with chronic thromboembolic pulmonary hypertension (CTEPH) and three animal models in vivo. Measurements and Main Results: The protein NEDD9 was identified in the hypoxia thrombosome network in silico. Compared with normoxia, hypoxia (0.2% O2) for 24 hours increased HIF-1α (hypoxia-inducible factor-1α)-dependent NEDD9 upregulation in vitro. Increased NEDD9 was localized to the plasma-membrane surface of cells from control donors and patients with CTEPH. In endarterectomy specimens, NEDD9 colocalized with the platelet surface adhesion molecule P-selectin. Our custom-made anti-NEDD9 Ab targeted the NEDD9-P-selectin interaction and inhibited the adhesion of activated platelets to pulmonary artery endothelial cells from control donors in vitro and from patients with CTEPH ex vivo. Compared with control mice, platelet-pulmonary endothelial aggregates and pulmonary hypertension induced by ADP were decreased in NEDD9-/- mice or wild-type mice treated with the anti-NEDD9 Ab, which also decreased chronic pulmonary thromboembolic remodeling in vivo. Conclusions: The NEDD9-P-selectin protein-protein interaction is a modifiable target with which to inhibit platelet-pulmonary endothelial adhesion and thromboembolic vascular remodeling, with potential therapeutic implications for patients with disorders of increased hypoxia signaling pathways, including CTEPH.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Alba GA, Samokhin AO, Wang RS, et al. NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. Am J Respir Crit Care Med. 2021. PMID: 33523764. doi:10.1164/rccm.202003-0719OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。